- Coordinator
- DIANA Biotechnologies, a.s., Czechia
- Runs
- 1 July 2026 to 30 June 2028
- Status
- Running
- EU funding
- €499k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- Coordination and Support Action
- Grant agreement
- 101309816
What the project is doing
In the project's own words, from its summary on CORDIS.
Sepsis is a life-threatening condition caused by a dysregulated immune response to infection, responsible for over 11M deaths annually. Rapid identification of the causative pathogen is essential, as each hour of delay in targeted treatment increases mortality by ~8%. Current diagnostics, such as blood culture, are slow (up to five days) and frequently yield false negatives, while existing PCR-based tools remain limited by narrow pathogen panels, low sensitivity in whole blood, and dependence on complex, costly instrumentation.
The SURPASS project, led by DIANA Biotechnologies, will advance SepsiSense, a next-generation molecular diagnostic tool enabling rapid, ultra-sensitive detection of sepsis-causing pathogens directly from whole blood. SepsiSense integrates proprietary PCR enzymes, inhibitor-resistant chemistry, and a novel deep multiplex design capable of detecting ~30 bacterial and fungal pathogens, and antibiotic resistance genes in a single reaction.
Its unique RNA–DNA co-detection approach provides superior sensitivity and enables assessment of pathogen viability and resistance activity, delivering clinically actionable results within 2 hours. Through SURPASS, DIANA will mature SepsiSense from early TRL 4 to TRL 6, expanding the pathogen panel, validating the assay across commercial PCR platforms, and aligning performance with IVDR standards. In parallel, the project will strengthen DIANA’s business and investor readiness through development of a market-validated business plan, IP and regulatory strategy, and partnerships with hospitals, KOLs, and diagnostic companies.
Offering high performance, affordability (~€25/test), and compatibility with existing PCR systems, SepsiSense will enable faster, more accurate diagnostics, support antibiotic stewardship, and reinforce Europe’s leadership and autonomy in advanced molecular healthcare technologies.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| DIANA Biotechnologies, a.s. | Vestec | Czechia | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI